In 2015, there were 61 IPOs across western stock exchanges, down from 87 in 2014, with companies raising $4.68 billion, compared to $6.3 billion in 2014. Total US and EU venture capital (VC) funding grew 34.4% and 46.4% to $7.04 billion and $2.02 billion, respectively, although the number of rounds for each region declined. To […]
Although energy firms are cutting costs and reducing employees due to bottoming oil prices, North American research organizations and companies are increasing efforts to enhance the productivity of oil production. By creating new labs and hiring more employees, research institutions are taking advantage of the slowdown in the oil industry to come up with new […]
US equity markets steadily advanced in March with the Dow Jones Industrial Average, S&P 500 and NASDAQ improving 7.1%, 6.6% and 6.8%, respectively. Investors reacted favorably to US Federal Reserve Chair Janet Yellen’s dovish stance, as she advocated a more cautious approach to policy changes due to the fragile global economic environment. Consequently, the US […]
Following each Pittcon (see IBO 3/15/16), IBO details the new products introduced at the show. These are products that began shipping in winter 2015 or later. Part 1 of this article appeared in the March 15 issue. The list is not all inclusive. Atomic Spectroscopy Alpha Resources displayed a new elemental analyzer from Eltra, the […]
Uppsala, Sweden and Tucson, AZ 3/16/16—Gyros, a Swedish provider of automated nanoliter-scale immunoassays, and Protein Technologies, a supplier of peptide synthesizers, have agreed to form Gyros Protein Technologies. “The fields of proteins and peptides have merged, and hence so have we, creating a biotherapeutics discovery-to-production offering ideally positioning us for future expansion,” commented Protein Technologies […]
Minneapolis, MN 3/31/16—Bio-Techne has purchased Zephyrus Biosciences for an undisclosed amount. Zephyrus’s Z1 System is designed for western blotting of individual cells. “This new technology brings this technique to the single-cell level, allowing us to address both homogeneous sample populations with our Simple Western platforms and now heterogeneous populations at the single-cell level with Zephyrus […]
Venlo, the Netherlands 3/29/16; Copenhagen, Denmark 3/29/16—QIAGEN has announced that it plans to submit a conditional voluntary takeover offer to Exiqon shareholders. QIAGEN will offer DKK 18 ($2.70 = DKK 6.67 = $1) per share, a 41.7% premium over Exiqon’s closing price on March 29, or DKK 683 million ($102 million). Publicly held Exiqon provides […]
Palo Alto, CA 3/18/16; Santa Clara, CA 3/20/16; Waltham, MA 3/20/16; Palo Alto, CA 3/21/16; Palo Alto, CA 3/22/16; Waltham, MA 3/22/16; Santa Clara, CA 3/23/16; Santa Clara, CA 3/28/16; Palo Alto, CA 3/28/16; Waltham, MA 3/28/16; Waltham, MA 3/31/16—On March 31, Affymetrix shareholders approved Thermo Fisher Scientific’s offer to acquire the company for $14 […]
Although the use of 2D cellular assays for drug discovery predominates, the adoption of 3D assays is steadily growing. Three-dimensional assays (also known as 3D microtissues) are self-generated clusters of cell colonies. Such assays provide greater physiological and morphological relevance compared to 2D assays, aiming to reduce drug candidate failures and the use of animal […]
Pay Invoice
Latest Blogs
-
LAUDA: Temperature Control Innovation
December 10, 2024 4:11 pm
-
Perseverance Forecasted for the Pharmaceutical Market for Analytical and Scientific Instrumentation
October 24, 2024 5:17 pm
-
M&A Activity in the Analytical Instrumentation and Lab Tools Market. 2021-2023
September 30, 2024 1:32 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
